SOPH (Sophia Genetics) Tax Provision : $-0.62 Mil (TTM As of Sep. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Sophia Genetics Tax Provision?

Sophia Genetics's tax provision for the three months ended in Sep. 2024 was $-0.13 Mil. Its tax provision for the trailing twelve months (TTM) ended in Sep. 2024 was $-0.62 Mil.

Sophia Genetics Tax Provision Historical Data

The historical data trend for Sophia Genetics's Tax Provision can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sophia Genetics Tax Provision Chart

Sophia Genetics Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Tax Provision

Get a 7-Day Free Trial

-0.16

1.89

-0.17

0.14

-0.49

Sophia Genetics Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Tax Provision	Get a 7-Day Free Trial															-0.30	-0.01	-0.32	-0.16	-0.13

Sophia Genetics Tax Provision Calculation

Tax to be paid.

Tax Provision for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.62 Mil.

Sophia Genetics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Sophia Genetics SA (NAS:SOPH) » Definitions » Tax Provision

Comparable Companies

Traded in Other Exchanges

90B:Germany

Address

La Pièce 12, Rolle, CHE, CH-1180

Website

https://www.sophiagenetics.com

Sophia Genetics SA is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It has built a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The Company had a physical presence in three countries outside of its headquarters in Switzerland: France, the United States, and Brazil.